Achieved significant ESG milestones in the first half of 2022

MEXICO CITY, July 25, 2022 /PRNewswire/ — Genomma Lab International, SAB de CV (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care companies in Mexico with an expanding international presence, announces that the Company’s Industrial Division has received EDGE (Design Excellence for Greater Efficiency) for each of its main buildings: pharmaceutical plant, personal care plant and distribution center.

EDGE is a green building standard and global certification system developed by the International Finance Corporation (IFC), the private arm of the World Bank, which certifies the design and resource efficiency of green buildings. The EDGE label is awarded to buildings that demonstrate resource efficiency of at least 20% in energy, water and embodied energy in materials. IFC created EDGE to address the need for a measurable and credible solution to prove the business case for green building and to unlock financial investment.

Genomma Lab’s industrial complex is the first pharmaceutical plant in the Western Hemisphere to meet EDGE certification standards.


Genomma’s personal care plant design provides 31% energy savings, 52% water savings and 41% less embodied energy in materials compared to the local benchmark. 86.64 tonnes of CO2 will therefore be saved annually.


Genomma’s OTC plant design provides 45% energy savings, 37% water savings and uses 42% less embodied energy in materials compared to the EDGE benchmark. 33.13 tonnes of CO2 will thus be saved annually.


Genomma’s distribution center design provides 26% energy savings, 54% water savings and uses 38% less embodied energy in materials compared to the EDGE benchmark. 227.29 tonnes of CO2 will thus be saved annually.

“It is a great honor to be EDGE Certified and to be the only pharmaceutical plant in the Western Hemisphere to receive EDGE Certification. We are committed to achieving Genomma’s ambitious ESG goals across our organization,” said Genomma Lab CEO. Jorge Brake. “That’s why one of our top priorities in Genomma’s 2025 sustainability strategy is sustainable product innovation with minimal environmental impact.”

He continued: “We are implementing technologies to treat 100% of the factory’s waste water to enable its reuse. We also ensure that our combined heat and power (CHP) plant provides 50% of the energy used in our industrial clusters, simultaneously generating energy from a single fuel source with a resulting cleaner energy consumption. »

Fernanda AguilarESG Director of Genomma Lab, added: “Other notable achievements in the first half of 2022 include:

  • Our industrial complex has achieved its “zero waste to landfill” objective
  • Secondary packaging of all products sold in Argentina certified for the use of sustainably managed forest resources
  • Genomma has been included in the “S&P/BMV Mexico ESG Index” for the third consecutive year
  • Launch of the new ecological shampoo “Tio Nacho”, a carbon-neutral packaging that incorporates recycled and recyclable materials.”

Please click on the following link to download our 2025 Sustainability Strategy:


About Genomma Lab International
Genome Laboratory InternationalSAB of VS.V. is one of the fastest growing pharmaceutical and personal care companies in the Latin America with an expanding international presence. Genome Lab develops, sells and markets a wide range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The company has a strong business model through a unique combination of new product development process, consumer-focused marketing, extensive retail distribution network and operating model. low-cost and highly flexible supply chain. For more information visit: www.genomic
Genomma Lab’s shares are listed on the Mexican Stock Exchange under the symbol “LABB” (Bloomberg:LABB:MM).

Note on forward-looking statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current beliefs and/or expectations of the Company and its management regarding its performance, business and future events. Forward-looking statements include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as “believe”, “anticipate”, “would expect”, “intend”, “will likely result”, or any other word or phrase of similar meaning. These statements are subject to a number of risks, uncertainties and assumptions. We caution you that a certain number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks relating to the impact of the global pandemic the of COVID-19, such as the extent and duration of the outbreak, government actions and restrictive measures implemented in response, significant delays, supply chain disruptions and other impacts on the business or the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products obtained by competitors; challenges inherent in developing new products; the Company’s ability to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, either internally or within the supply chain; material adverse litigation or governmental action, including related to product liability claims; changes in applicable laws and regulations, including tax laws; changes in behavior and spending patterns of buyers of products and services; financial instability of international economies and legal systems and sovereign risk. A list and additional descriptions of such risks, uncertainties and other factors are contained in the Company’s filings with Bolsa Mexicana de Valores. Any forward-looking statements made in this release speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab International, SAB de CV


Comments are closed.